CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-09 | Marriott Tina President and COO | Shares withheld for taxes | −2,800 | $10.09 | $28K | 645,361 |
| 2024-02-09 | Marriott Tina President and COO | Grant or award · Stock Option (Right to Buy) | +447,917 | 447,917 | ||
| 2024-02-09 | Gibson Christopher Chief Executive Officer | Grant or award | +11,148 | 785,851 | ||
| 2024-02-09 | Gibson Christopher Chief Executive Officer | Grant or award | +333,449 | 1,119,300 | ||
| 2024-02-09 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −3,233 | $10.09 | $33K | 1,116,067 |
| 2024-02-09 | Gibson Christopher Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +666,898 | 666,898 | ||
| 2024-02-07 | Gibson Christopher Chief Executive Officer | Conversion | +10,000 | 801,725 | ||
| 2024-02-07 | Gibson Christopher Chief Executive Officer | Gift | −10,000 | 791,725 | ||
| 2024-02-07 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 822,975 |
| 2024-02-07 | Gibson Christopher Chief Executive Officer | Sale | −48,272 | $9.22 | $445K | 774,703 |
| 2024-02-07 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −31,250 | 343,750 | ||
| 2024-02-07 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −10,000 | 6,471,496 | ||
| 2024-02-06 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $9.30 | $106K | 7,312,917 |
| 2024-01-25 | Larson Tina Marriott President and COO | Exercise or conversion 10b5-1 | +8,000 | $1.06 | $8K | 422,584 |
| 2024-01-25 | Larson Tina Marriott President and COO | Sale 10b5-1 | −8,000 | $10.35 | $83K | 414,548 |
| 2024-01-25 | Larson Tina Marriott President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −8,000 | 504,000 | ||
| 2024-01-23 | Borgeson Blake Director | Sale 10b5-1 | −20,054 | $10.58 | $212K | 7,324,364 |
| 2024-01-17 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 1,006,014 |
| 2024-01-17 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $10.25 | $256K | 981,014 |
| 2024-01-17 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,035,135 |
Page 25 of 41 · 805 trades